N-(2-硝基苯基)-1,4-苯二胺 | 31067-22-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(2-硝基苯基)-1,4-苯二胺
• 英文名称: N¹-(2-nitrophenyl)benzene-1,4-diamine
• 英文别名: 2-nitro-4'-aminodiphenylamine；N-(2-nitro-phenyl)-p-phenylenediamine；N-(2-Nitro-phenyl)-p-phenylendiamin；2'-Nitro-4-amino-diphenylamin；2-Nitro-N-(4-aminophenyl)aniline；N~1~-(2-Nitrophenyl)benzene-1,4-diamine；4-N-(2-nitrophenyl)benzene-1,4-diamine
• CAS: 31067-22-8
• 化学式: C₁₂H₁₁N₃O₂
• mdl: MFCD09947307
• 分子量: 229.238
• InChiKey: PABVMKMWZAGWIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.9
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2921590090

反应信息

• 作为反应物：
  描述：

  N-(2-硝基苯基)-1,4-苯二胺 在 盐酸 、 palladium on activated charcoal 、 potassium hexacyanoferrate(III) 作用下， 以 水 、 乙酸乙酯 为溶剂， 生成 2-氨基吩嗪
  参考文献：
  名称：

  Rates of formation of some phenazines by cyclization of di- and monoimines of N-(2-aminophenyl)-p-benzoquinone

  摘要：

  DOI：

  10.1021/jo00319a027
• 作为产物：
  描述：

  硝基氯苯 、 对苯二胺 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 以98%的产率得到N-(2-硝基苯基)-1,4-苯二胺
  参考文献：
  名称：

  Cu（0）@Al 2 O 3 / SiO 2 NPs：一种有效的可重复使用的催化剂，用于芳基氯化物与胺和苯胺的交叉偶联反应†

  摘要：

  研究了芳基氯化物与各种烷基/芳基胺的C–N交叉偶联反应，该反应由浸渍在氧化铝/二氧化硅载体（Cu（0）@Al 2 O 3 / SiO 2）上的铜纳米颗粒催化。使用XRD，XPS，HR-TEM，BET表面积，SEM-EDAX，H 2表征制备的催化剂的固有物理化学和结构性质-TPR和ICP-AES技术。该催化剂在各种烷基/芳基胺（包括挑战性苯胺）与芳基氯化物的交叉偶联中显示出极好的反应性和功效。与其他已报道的方法相比，该催化剂具有简便，反应条件温和，收率高和对C–N交联的官能团耐受性强等显着优势。而且，这种原子经济的方法不需要额外的配体或助催化剂/活化剂。该Cu（0）@Al 2 O 3 / SiO 2催化剂被有效地用于7-氯-4-（4-（2-（硝基苯苯基）哌嗪-1-基）喹诺酮的克级合成（2k）。通过连续使用五次来检查催化剂的坚固性。

  DOI：

  10.1039/c5ra19337k

文献信息

• Bis (benzimidazole) derivatives serving as potassium blocking agents
  申请人：Neurosearch A/S

  公开号：US06194447B1

  公开（公告）日：2001-02-27

  This invention relates to novel potassium channel blocking agents, and their use in the preparation of pharmaceutical compositions. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, in particular asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic hearth disease, angina pectoris, coronary hearth disease, traumatic brain injury, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.

  这项发明涉及新型钾通道阻滞剂，以及它们在制备药物组合物中的应用。 此外，该发明针对用于治疗或缓解与钾通道活性相关的疾病或障碍的药物组合物，特别是哮喘、囊性纤维化、慢性阻塞性肺病和鼻涕、痉挛、血管痉挛、冠状动脉痉挛、肾脏疾病、多囊肾病、膀胱痉挛、尿失禁、膀胱排出道梗阻、肠易激综合征、胃肠功能障碍、分泌性腹泻、缺血、脑缺血、缺血性心脏病、心绞痛、冠状动脉心脏病、创伤性脑损伤、精神病、焦虑、抑郁症、痴呆、记忆和注意力缺陷、阿尔茨海默病、痛经、嗜睡症、雷诺氏病、间歇性跛行、Sjorgren综合征、偏头痛、心律失常、高血压、缺席性癫痫发作、肌肉肌无力症、口干症、糖尿病II型、胰岛素过多症、早产、秃头、癌症和免疫抑制。
• Potassium channel blocking agents
  申请人：NeuroSearch A/S

  公开号：US20020049246A1

  公开（公告）日：2002-04-25

  This invention relates to novel potassium channel blocking agents, and their use in the preparation of pharmaceutical compositions. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, in particular asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic hearth disease, angina pectoris, coronary hearth disease, traumatic brain injury, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.

  本发明涉及新型钾通道阻滞剂及其在制备药物组合物中的应用。此外，本发明还涉及用于治疗或缓解与钾通道活性有关的疾病或疾病的药物组合物，特别是哮喘、囊性纤维化、慢性阻塞性肺疾病和流涕、惊厥、血管痉挛、冠状动脉痉挛、肾脏疾病、多囊肾病、膀胱痉挛、尿失禁、膀胱出流道梗阻、肠易激综合征、胃肠功能障碍、分泌性腹泻、缺血、脑缺血、缺血性心脏病、心绞痛、冠心病、创伤性脑损伤、精神病、焦虑、抑郁症、痴呆、记忆和注意力缺陷、阿尔茨海默病、痛经、嗜睡病、雷诺氏病、间歇性跛行、Sjorgren综合征、偏头痛、心律失常、高血压、失神发作、肌萎缩性肌肉营养不良、干口症、2型糖尿病、高胰岛素血症、早产、秃发、癌症和免疫抑制。
• Bis(benzimidazole) derivatives serving as potassium blocking agents
  申请人：Neurosearch A/S

  公开号：US06569880B2

  公开（公告）日：2003-05-27

  This invention relates to novel potassium channel blocking agents, and their use in the preparation of pharmaceutical compositions. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, in particular asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic hearth disease, angina pectoris, coronary hearth disease, traumatic brain injury, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.

  本发明涉及新型钾通道阻滞剂及其在制备药物组合物中的使用。此外，本发明针对与钾通道活动相关的疾病或障碍，特别是哮喘、囊性纤维化、慢性阻塞性肺疾病和流涕、惊厥、血管痉挛、冠状动脉痉挛、肾脏疾病、多囊肾病、膀胱痉挛、尿失禁、膀胱出口梗阻、肠易激综合征、胃肠功能障碍、分泌性腹泻、缺血、脑缺血、缺血性心脏病、心绞痛、冠心病、创伤性脑损伤、精神病、焦虑、抑郁、痴呆、记忆和注意力缺陷、阿尔茨海默病、痛经、嗜睡症、雷诺氏病、间歇性跛行、Sjorgren综合征、偏头痛、心律失常、高血压、失神发作、肌无力症、口干症、2型糖尿病、高胰岛素血症、早产、脱发、癌症和免疫抑制等疾病或障碍的治疗或缓解的药物组合物。
• Compounds for inflammation and immune-related uses
  申请人：Chen Shoujun

  公开号：US20070249661A1

  公开（公告）日：2007-10-25

  The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein X, Y, A, Z, L and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions and immune disorders.

  本发明涉及公式（I）的化合物：或其药学上可接受的盐，溶剂合物，包合物或前药，其中X，Y，A，Z，L和n在此定义。这些化合物可用作免疫抑制剂，并用于治疗和预防炎症疾病和免疫性疾病。
• Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
  申请人：Chen Shoujun

  公开号：US20070254912A1

  公开（公告）日：2007-11-01

  The invention relates to compounds of formula (XVI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein Y 2 , Z, L 1 , R 9 , R 10 , m and u are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, immune disorders, and allergic disorders.

  该发明涉及公式（XVI）的化合物：或其药学上可接受的盐，溶剂化合物，包合物或前药，其中Y2，Z，L1，R9，R10，m和u在此被定义。这些化合物可用作免疫抑制剂，并用于治疗和预防炎症疾病，免疫性疾病和过敏性疾病。